DT-Web

DB01298 - Sulfacytine


Identification
Name Sulfacytine
Accession Number DB01298
Type small molecule
Description Sulfacytine is a short-acting sulfonamide. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Sulfacytine is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 294.33
Groups approved
Monoisotopic Weight 294.078661024
Pharmacology
Indication Used orally in the treatment of acute urinary tract infections.
Mechanism of action Sulfacytine is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.
Absorption Well absorbed following oral administration.
Protein binding Not Available
Biotransformation Not Available
Route of elimination Not Available
Toxicity Not Available
Affected organisms
  • Bacteria
Interactions
Drug Interactions
Drug Mechanism of interaction
Chlorpropamide Sulfonamide/sulfonylurea: possible hypoglycemia
Methotrexate The sulfamide increases the toxicity of methotrexate
Food Interactions Not Available

Targets


Dihydropteroate synthase
Name Dihydropteroate synthase
Gene Name folP
Pharmacological action yes
Actions inhibitor
References
  • Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. - Pubmed
  • Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. - Pubmed
  • Hughes J, Roberts LC, Coppridge AJ: Sulfacytine: a new sulfonamide. Double-blind comparison with sulfisoxazole in acute uncomplicated urinary tract infections. J Urol. 1975 Dec;114(6):912-4. - Pubmed
DTHybrid score 0.8156

Predictions


Id Partner name Gene Name Score
5359 Dihydropteroate synthase folP 0.8156
7175 Dihydropteroate synthase sulI 0.8156
587 Serum albumin ALB 0.1048
4757 Cytochrome P450 2C9 CYP2C9 0.0802
6103 Arylamine N-acetyltransferase 1 NAT1 0.0248
4119 Cytochrome P450 2D6 CYP2D6 0.0204
4924 Cytochrome P450 2C8 CYP2C8 0.0182
137 FolC bifunctional protein [Includes: Folylpolyglutamate synthase folC 0.0177
6102 Arylamine N-acetyltransferase 2 NAT2 0.0147
4512 Cytochrome P450 3A4 CYP3A4 0.0145
5718 Cytochrome P450 2A6 CYP2A6 0.0136
6013 Cytochrome P450 2E1 CYP2E1 0.0123
6030 Cytochrome P450 2B6 CYP2B6 0.0122
6016 Cytochrome P450 2C19 CYP2C19 0.011
6018 UDP-glucuronosyltransferase 1-9 UGT1A9 0.0101
20 Prostaglandin G/H synthase 1 PTGS1 0.0079
↑